We are live on ! Find out more
RGN

REGENERX BIOPHARMACEUTICALS
RGN

Delisted

RGN was delisted on the 22nd of December, 2010.

Back to rankings

1 hedge funds and large institutions have $1.39K invested in REGENERX BIOPHARMACEUTICALS in 2022 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

39% more capital invested

Capital invested by funds: $1K → $1.39K (+$389)

0% more funds holding

Funds holding: 1 → 1 (0)

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter

RGN Hedge Fund Activity: Q4 2022 in Review

1 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in REGENERX BIOPHARMACEUTICALS (RGN) for Q4 2022, worth a combined $1.39K — up 39% from $1K a quarter earlier.

Fund positioning in RGN was balanced in Q4 2022: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 1 institutional investor held REGENERX BIOPHARMACEUTICALS (RGN) as of Q4 2022, unchanged from Q3 2022.
  • Funds reported $1.39K of REGENERX BIOPHARMACEUTICALS stock for Q4 2022, up 39% quarter-over-quarter.
  • 0 funds opened new REGENERX BIOPHARMACEUTICALS positions in Q4 2022 and 0 closed out.

Based on aggregated 13F filings for Q4 2022.